Research institution
Fujian Cancer Hospital Clinical Trials
Studies where Fujian Cancer Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 65Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis
Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma
This study is a prospective, multicenter, open-label, exploratory phase II clinical trial aimed at evaluating the efficacy and safety of serplulimab combined with DOS, lenvatinib, and PIPACS in patients with oligometastatic…
- Trial name
- NCT07902648
- Testing
- Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC
- Volunteers
- 42 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma, Local Recurrence
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence.
- Trial name
- NCT07331428
- Testing
- MRG003, Tislelizumab, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Breast Neoplasm Female, Triple -Negative Breast Cancer
Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
This study is a multicenter, prospective, observational cohort study to evaluate the predictive performance of pre-treatment DCE-MRI-based artificial intelligence (AI) models for neoadjuvant chemotherapy benefit in locally…
- Trial name
- NCT07880600
- Testing
- Pre-treatment DCE-MRI-based AI model
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Rectal Cancer
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.
- Trial name
- NCT07469306
- Testing
- Modified Short-course radiotherapy, Long-course radiotherapy, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer Liver Metastasis
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
- Trial name
- NCT06788171
- Testing
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy, Bevacizumab, Capecitabine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced or Metastatic Renal Cell Carcinoma
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.
- Trial name
- NCT07470840
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Fujian Cancer Hospital
HER2 + Breast Cancer, Advanced Breast Cancer
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
This study is a single-arm, exploratory clinical trial, aiming to include patients with HER2-positive advanced breast cancer. It intends to explore the efficacy and safety of trastuzumab combined with pyrotinib, capecitabine ±…
- Trial name
- NCT07766772
- Testing
- Trastuzumab Rezetecan, Pyrotinib, trastuzumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Non-small Cell Lung Cancer(NSCLC)
Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC
Patients with advanced non-small cell lung cancer (NSCLC) who experience disease progression after standard systemic therapies or are unable to tolerate such therapies have limited subsequent treatment options.
- Trial name
- NCT07738367
- Testing
- Bronchial Arterial Chemoembolization (BACE), Systemic anti-tumor combination medications
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
HR+/HER2- Breast Cancer, Breast Neoplasms
Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
This study is a multicenter, prospective, observational cohort study to evaluate the predictive performance of pre-treatment DCE-MRI-based artificial intelligence (AI) models for neoadjuvant chemotherapy benefit in HR+/HER2…
- Trial name
- NCT07702708
- Testing
- Pre-treatment DCE-MRI-based AI model
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Fujian Cancer Hospital
HR+/HER2- Breast Cancer, Breast Neoplasms
Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
This study is a single-center, prospective, open-label exploratory clinical study to assess the efficacy and safety of kumorixilib combined with capecitabine and letrozole as neoadjuvant therapy in patients with HR+/HER2- stage…
- Trial name
- NCT07691333
- Testing
- Kumorixilib 180mg, Capecitabine 500mg, Letrozole 2.5mg
- Where
- 3 sites in China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital